Dr. Oh on Results of Chemotherapy Versus ARTA in Prostate Cancer

Video

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

In this study, 345 patients who showed a lack of response to first-line ARTA were enrolled using Altos electronic medical records. Patients received either second-line docetaxel or cabazitaxel, or alternative ARTA.

Oh concludes that treatment with second-line chemotherapy proved more suitable for this patient subset than ARTA.

<<<

View more from the 2017 Genitourinary Cancers Symposium

Related Videos
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD
Daniel Spratt, MD
Daniel Spratt, MD
Philip J. Koo, MD
Patrick I. Borgen, MD
Anthony D'Amico MD, PhD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania